Who Should Use This Combination and When to Pause Levothyroxine and semaglutide are appropriate together for most patients with well-controlled hypothyroidism or Hashimoto's disease who also meet clinical criteria for GLP-1 therapy (BMI 27 with weight-related comorbidities, or BMI 30)
At the suggestion of her endocrinologist, she started semaglutide in April 2022 and switched to tirzepatide after an insurance change, losing 41 pounds so far, and nearing her goal
The drugs progress comes as Eli Lilly continues to expand its obesity portfolio, which already includes the injectable Zepbound and the oral pill Foundayo
Dick, P., Costa, C., Fayolle, K., Grandjean, M., Khoshbeen, A., & Tissot, R